Clinical Trial Update: Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epigallocatechin-3-gallate (EGCG) for skin prevention in breast cancer patients undergoing adjuvant radiotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Dermatitis

Drugs mentioned

• Epigallocatechin-3-Gallate (epigallocatechin-3-gallate)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Breast Neoplasms, Dermatitis | Phase 2 | Status: UNKNOWN